US4450165A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Dihydropyridine compounds
Assignee: Tanabe Pharma Corp
•
Filing: 1982-06-04
•
Granted: 1984-05-22
•
Expires: 2002-06-04
Abstract
Abstract A dihydropyridine compound of the formula: <IMAGE> or a pharmaceutically acceptable acid addition salt thereof, wherein Het is 5- or 6-membered aromatic heteroaryl, R1 and R2 are each lower alkyl, R3 is lower alkyl, R4 is hydrogen, lower alkyl or aralkyl, R5 is lower alkyl or aralkyl, and n is 1 or 2. Such compounds are useful as therapeutic agents for myocardial and cerebral ischemic syndroms and hypertension.
Inventors
- 👤 Kazuhiko Araki
- 👤 Hideki Ao
- 👤 Tomohiko Kimura
- 👤 Kenichi Aihara
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 12:26
CPC Classifications
C; C07; C07D; C07D405/00; C07D401/00; C07D401/02; C07D401/12; A; A61; A61P; A61P9/00; A61P9/08; A61P9/12; C07D307/00; C07D307/02; C07D307/34; C07D307/38; C07D307/52; C07D333/00; C07D333/02; C07D333/04; C07D333/06; C07D333/14; C07D333/20; C07D405/02; C07D405/12; C07D409/00; C07D409/02; C07D409/12; C07D413/00; C07D413/02; C07D413/12; C07D417/00; C07D417/02; C07D417/12
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
88 words
A dihydropyridine compound of the formula: ##STR15## or a pharmaceutically acceptable acid addition salt thereof, wherein Het is 5- or 6-membered aromatic heteroaryl selected from the group consisting of furyl, thienyl, pyridyl, thiazolyl, oxazolyl, isooxazolyl, pyrrolyl, imidazolyl, pyrimidinyl or 3,4-dihydrocarbostyril, and said heteroaryl being unsubstituted or substituted by a lower alkyl or halogen, R 1 and R 2 are each lower alkyl, R 3 is lower alkyl, R 4 is hydrogen, lower alkyl or aralkyl, R 5 is lower alkyl or aralkyl, and n is 1 or 2.
Claim 2
Dependent Claim
88 words
A dihydropyridine compound of the formula: ##STR15## or a pharmaceutically acceptable acid addition salt thereof, wherein Het is 5- or 6-membered aromatic heteroaryl selected from the group consisting of furyl, thienyl, pyridyl, thiazolyl, oxazolyl, isooxazolyl, pyrrolyl, imidazolyl, pyrimidinyl or 3,4-dihydrocarbostyril, and said heteroaryl being unsubstituted or substituted by a lower alkyl or halogen, R 1 and R 2 are each lower alkyl, R 3 is lower alkyl, R 4 is hydrogen, lower alkyl or aralkyl, R 5 is lower alkyl or aralkyl, and n is 1 or 2.
Claim 3
Dependent Claim
7 words
The compound of claim 1: 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methylester-5-[2-(N-benzyl-N-methylamino)-1-(2-furyl)ethyl]ester.
Claim 4
Dependent Claim
7 words
The compound of claim 1: 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methylester-5-[2-(N-benzyl-N-methylamino)-1-(2-thienyl)ethyl]ester.
Claim 5
Dependent Claim
7 words
The compound of claim 1: 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methylester-5-[2-(N-benzyl-N-methylamino)-1-(2-pyridyl)ethyl]ester.
Claim 6
Dependent Claim
7 words
The compound of claim 1: 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methylester-5-[2-(N-benzyl-N-methylamino)-1-(3-pyridyl)ethyl]ester.
Claim 7
Dependent Claim
7 words
The compound of claim 1: 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methylester-5-[2-(N-benzyl-N-methylamino)-1-(4-pyridyl)ethyl]ester.
Claim 8
Dependent Claim
7 words
The compound of claim 1: 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methylester-5-[2-(N-benzyl-N-methylamino)-1-(3-thienyl)ethyl]ester.
Claim 9
Dependent Claim
7 words
The compound of claim 1: 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methylester-5-[2-diethylamino-1-(2-thienyl)ethyl]ester.
Claim 10
Dependent Claim
7 words
The compound of claim 1: 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methylester-5-[2-(N-benzyl-N-methylamino)-1-(1-methyl-3,4-dihydrocarbostyril-6-yl)ethyl]ester.
Claim 11
Dependent Claim
39 words
A pharmaceutical composition for use in the treatment of myocardial and cerebral ischemic syndromes and hypertension comprising the compound of claim 1 in combination with a pharmaceutically acceptable inert carrier, said compound being present in a therapeutically effective amount.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-05-22 | 1987-11-21 | 1988-05-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-05-22 | 1991-11-21 | 1992-05-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-05-22 | 1995-11-21 | 1996-05-22 | $7700.00 | Window Closed / Lapsed |